Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02047253 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment

A Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by University of Alabama at Birmingham.

Completed
Registry status
Phase 2
Development phase
28
Enrollment target
4
Study locations

NCT02047253 is a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 28 participants, below the 198-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (86% lower). The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02047253, a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, has completed, sponsored by University of Alabama at Birmingham.

COMPLETED
Registry status
Phase 2
Development phase
28 participants
Enrollment target
4
Study locations

Study Summary

This study will test how effective the drug, Carfilzomib, reduces progression of prostate cancer in patients who have previously received chemotherapy and androgen inhibitors. Carfilzomib is approved for multiple myeloma but is not approved for prostate cancer. Therefore, it is considered investigational. Other approved methods of treatment for metastatic prostate cancer have demonstrated only modest benefits. Novel and tolerable agents are necessary to make further gains and extend overall survival.

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer

Interventions

  • DRUG Dexamethasone
  • DRUG Carfilzomib
  • DRUG Acyclovir

Study Locations (4)

Alabama

  • Birmingham VA Medical Center - Birmingham
  • University of Alabama at Birmingham - Birmingham

Georgia

  • Cancer Life Center, Navicent Health - Macon

Louisiana

  • University of Tulane - New Orleans

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2014-04
Est. Completion 2017-07-14
Phase Phase 2

Sponsor

University of Alabama at Birmingham

1,160 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02047253

The ClinicalTrials.gov registry entry for NCT02047253 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (86% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.

NCT02047253 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Alabama, Georgia, Louisiana.

Frequently Asked Questions

What is clinical trial NCT02047253 about?

NCT02047253 is a clinical study titled "Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment". This study will test how effective the drug, Carfilzomib, reduces progression of prostate cancer in patients who have previously received chemotherapy and androgen inhibitors. Carfilzomib is approved for multiple myeloma but is not approved for prostate cancer. Therefore, it is considered investigat...

What is the current status of trial NCT02047253?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2014-04. Estimated completion is 2017-07-14.

What conditions does trial NCT02047253 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT02047253?

The interventions under investigation include: Dexamethasone (DRUG), Carfilzomib (DRUG), Acyclovir (DRUG).

Who is sponsoring clinical trial NCT02047253?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02047253 being conducted?

This trial has 4 study locations across Alabama, Georgia, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Castration-Resistant Prostate Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.